Literature DB >> 28453752

NANO, a practical scale for neurologic assessments in patients with brain tumors?

Warren Mason1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28453752      PMCID： PMC5464456          DOI： 10.1093/neuonc/nox048

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 2.  Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations.

Authors:  Jeremy C Hobart; Stefan J Cano; John P Zajicek; Alan J Thompson
Journal:  Lancet Neurol       Date:  2007-12       Impact factor: 44.182

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.

Authors:  Jaime Gállego Pérez-Larraya; Marion Lahutte; Gregorio Petrirena; Germán Reyes-Botero; Alberto González-Aguilar; Caroline Houillier; Rémy Guillevin; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Neuro Oncol       Date:  2012-04-04       Impact factor: 12.300

Review 5.  The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Authors:  Lakshmi Nayak; Lisa M DeAngelis; Alba A Brandes; David M Peereboom; Evanthia Galanis; Nancy U Lin; Riccardo Soffietti; David R Macdonald; Marc Chamberlain; James Perry; Kurt Jaeckle; Minesh Mehta; Roger Stupp; Alona Muzikansky; Elena Pentsova; Timothy Cloughesy; Fabio M Iwamoto; Joerg-Christian Tonn; Michael A Vogelbaum; Patrick Y Wen; Martin J van den Bent; David A Reardon
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

6.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Roger Stupp; Monika E Hegi; Thierry Gorlia; Sara C Erridge; James Perry; Yong-Kil Hong; Kenneth D Aldape; Benoit Lhermitte; Torsten Pietsch; Danica Grujicic; Joachim Peter Steinbach; Wolfgang Wick; Rafał Tarnawski; Do-Hyun Nam; Peter Hau; Astrid Weyerbrock; Martin J B Taphoorn; Chiung-Chyi Shen; Nalini Rao; László Thurzo; Ulrich Herrlinger; Tejpal Gupta; Rolf-Dieter Kortmann; Krystyna Adamska; Catherine McBain; Alba A Brandes; Joerg Christian Tonn; Oliver Schnell; Thomas Wiegel; Chae-Yong Kim; Louis Burt Nabors; David A Reardon; Martin J van den Bent; Christine Hicking; Andriy Markivskyy; Martin Picard; Michael Weller
Journal:  Lancet Oncol       Date:  2014-08-19       Impact factor: 41.316

Review 8.  Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

Authors:  Olivier L Chinot; David R Macdonald; Lauren E Abrey; Gudrun Zahlmann; Yannick Kerloëguen; Timothy F Cloughesy
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081
  8 in total
  1 in total

1.  Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases.

Authors:  Ariane Steindl; Sarah Yadavalli; Katharina-Anna Gruber; Maria Seiwald; Brigitte Gatterbauer; Karin Dieckmann; Josa M Frischer; Thomas Klikovits; Sabine Zöchbauer-Müller; Anna Grisold; Mir Ali Reza Hoda; Christine Marosi; Georg Widhalm; Matthias Preusser; Anna Sophie Berghoff
Journal:  Cancer       Date:  2020-07-17       Impact factor: 6.860
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.